<DOC>
	<DOCNO>NCT01040026</DOCNO>
	<brief_summary>High-dose chemotherapy melphalan autologous hematopoietic stem cell transplantation ( HSCT ) consider standard treatment patient multiple myeloma . While autologous HSCT may induce remission patient resistant standard chemotherapy , show lead long-lasting disease control subgroup patient , procedure curative . Given enough time absence compete cause death , patient eventually relapse auto-HSCT . The potentially curative approach currently available treatment multiple myeloma ( MM ) stem cell trans-plantation allogeneic donor . Allogeneic HSCT eradicate residual myeloma cell T-cell mediate graft-versus-tumor effect . Allogeneic HSCT , however , associate significant risk graft-versus-host disease use therefore limited young patient high risk dis-ease . Malignant plasma cell multiple myeloma also sensitive natural killer cell lysis . Natural killer cell cause graft-versus-host disease , lead interest therapeutic use patient multiple myeloma . We previously show immunomagnetic separation highly pure NK cell product leukapheresis possible cell expand 100-fold GMP-compatible setting . The current study aim test tolerability feasibility infusion vitro expanded haploidentical NK cell patient melphalan 200mg/m2 high dose chemotherapy autologous HSCT 10 patient . If feasible , data provide basis prospective study .</brief_summary>
	<brief_title>Expanded Natural Killer ( NK ) Cells Multiple Myeloma Study</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>&gt; 18 year , multiple myeloma indication autologous HSCT Available related haploidentical donor Written inform consent Patients schedule autologous/allogeneic tandem HSCT</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>